Pharmacokinetic interaction between AZD3480 and Donepezil
Study identifier:D3690C00005
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Terminated/Withdrawn
Official Title
A double-blind, randomised, cross-over, placebo-controlled study of repeated oral doses of AZD3480 and a single dose of donepezil to evaluate the pharmacokinetic interaction between AZD3480 and donepezil in healthy extensive and poor metabolisers of CYP2D6
Medical condition
Alzheimer's disease
Phase
Phase 1
Healthy volunteers
Yes
Study drug
AZD3480, Donepezil
Sex
All
Actual Enrollment
33
Study type
Interventional
Age
20 Years - 60 Years
Date
Study Start Date: 01 Dec 2008
Primary Completion Date: 01 Dec 2008
Study Completion Date: 01 Dec 2008
Study design
Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Crossover Assignment
Masking: Double Blind
Primary Purpose: Basic Science
Verification:
Verified 01 Aug 2014 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: A AZD3480 + Donepezil | Drug: AZD3480 18 total doses of 40 mg, on days 1-18 Drug: Donepezil One single dose of mg on day 5 |
Contacts
Investigators
Principal Investigator
Hans Göran Hårdemark
AstraZeneca R&D, Sodertalje, Sweden
